Due to the higher PD-L1 expression and TIL infiltration of EBV+ GC, clinical trials of the PD-1 inhibitor pembrolizumab have achieved a 100% overall response rate (ORR) in 6 patients with EBV+ metastatic GC [7]. Here, CD274 is linked to gastric cancer.